Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novo Nordisk AS's quarterly cash and cash equivalents
declined
from Dec. 2025 (€3,543.25 Mil) to Mar. 2026 (€2,826.61 Mil) but then
increased
from Mar. 2026 (€2,826.61 Mil) to Jun. 2026 (€5,948.94 Mil).
Novo Nordisk AS's annual cash and cash equivalents
increased
from Dec. 2023 (€1,930.92 Mil) to Dec. 2024 (€2,099.17 Mil) and
increased
from Dec. 2024 (€2,099.17 Mil) to Dec. 2025 (€3,543.25 Mil).
Novo Nordisk AS (WBO:NNO2) Cash And Cash Equivalents Explanation
A high number means either:
1) The company has competitive advantage generating lots of cash
2) Just sold a business or bonds (not necessarily good)
A low stockpile of cash usually means poor to mediocre economics.
There are 3 ways to create large cash reserve.
1) Sell new bonds or equity to public
2) Sell business or asset
3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)
When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.
Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.
Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.
Be Aware
Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.
Novo Nordisk AS Cash And Cash Equivalents Related Terms
Novo Nordisk AS Cash And Cash Equivalents Historical Data
* Premium members only.
The historical data trend for Novo Nordisk AS's Cash And Cash Equivalents can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Nordisk AS Cash And Cash Equivalents Calculation
Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.
What does a Cash And Cash Equivalents of €5,949 Mil mean?
Novo Nordisk AS (WBO:NNO2) has a Cash And Cash Equivalents of €5,949 Mil as of Jun. 2026. Cash and cash equivalents represents the total cash and other short-term investments on hand. View historical data on Novo Nordisk AS and its competitors.
Is Novo Nordisk AS's Cash And Cash Equivalents too high?
Novo Nordisk AS's current Cash And Cash Equivalents is €5,949 Mil. Overall, Novo Nordisk AS has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Cash And Cash Equivalents compare to LLY and JNJ?
Novo Nordisk AS's Cash And Cash Equivalents of €5,949 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash And Cash Equivalents for a Drug Manufacturers company?
A good Cash And Cash Equivalents depends on the Drug Manufacturers industry context. However, Cash And Cash Equivalents should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash And Cash Equivalents mean?
A high Cash And Cash Equivalents can signal that a stock is expensive relative to its fundamentals. Cash and cash equivalents represents the total cash and other short-term investments on hand. View historical data on Novo Nordisk AS and its competitors. Novo Nordisk AS's current Cash And Cash Equivalents is €5,949 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (WBO:NNO2) is currently considered Significantly Undervalued. The stock's GF Value™ is €93.94, compared to a current price of €40.71 — trading 56.7% below its estimated fair value. The current Cash And Cash Equivalents is €5,949 Mil. Novo Nordisk AS's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash And Cash Equivalents calculated?
Cash And Cash Equivalents is calculated from a company's financial statements. For Novo Nordisk AS (WBO:NNO2), the current Cash And Cash Equivalents is €5,949 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (WBO:NNO2) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of €40.71 is trading 56.7% below its estimated GF Value™ of €93.94.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for WBO:NNO2:
Cash And Cash Equivalents: €5,949 Mil
GF Value™: €93.94 vs. price of €40.71 (56.7% below fair value)
No single metric tells the full story. See the WBO:NNO2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
80GF Score
Get the complete analysis for WBO:NNO2
Cash And Cash Equivalents is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:NNO2 has been successfully added to your 
